NanoVibronix to rebrand, explore strategic alternatives for legacy technologies

NanoVibronix (NAOV) issued a letter to shareholders. The company said, “Since assuming the role of CEO in June 2025, our team has completed a comprehensive review of our operations, technologies and market opportunities. Throughout this process, our objective has remained clear: to focus on the opportunities that can deliver the greatest long-term value for shareholders and execute on them successfully. It became clear from this review that our ENvue(R) feeding-tube placement system (“ENvue”), which was merged into NanoVibronix in early 2025, is our strongest and most scalable growth platform. ENvue is 510(k) FDA-cleared, commercially available and already improving clinical workflows and patient outcomes across U.S. hospitals. By providing real-time anatomical navigation, the system assists clinicians in performing enteral-tube placements with greater confidence and efficiency. We believe that ENvue’s ability to deliver live guidance positions it as a modern solution in a large and growing market. In the U.S. alone, the enteral feeding devices market is projected to reach approximately $1.8 billion by 20301, representing meaningful upside potential… We already have an established customer base of 38 hospitals, providing a strong foundation for expansion and validation. To fully capitalize on the market potential of ENvue, we are implementing a multi-phase roadmap to accelerate adoption and revenue growth and expand hospital penetration. In addition to commercialization, we continue to invest in targeted research and development programs that support both near-term improvements and longer-term platform expansion including pediatric applications, imaging-overlay technology and vascular-access navigation. These initiatives are designed to drive measurable sales growth, expand hospital adoption and reinforce ENvue’s position as a next-generation navigation platform in enteral feeding and critical-care procedures. To reflect our new strategic direction, we are planning to rebrand the company by changing the name from NanoVibronix to ENvue Medical, accompanied by a new NASDAQ ticker symbol. This rebranding marks a new phase for the company: one defined by precision enteral access, technology-driven growth and clinical excellence. With ENvue Medical as the foundation for our future, we are actively exploring strategic alternatives for the legacy NanoVibronix technologies. Potential options such as partnerships or divestitures are intended to maximize value while allowing us to focus fully on our core strength in enteral navigation.”